Search Results - "Su, Wuyun"
-
1
miR-655-3p inhibits cell migration and invasion by targeting pituitary tumor-transforming 1 in non-small cell lung cancer
Published in Bioscience, biotechnology, and biochemistry (01-09-2019)“…miR-655-3p functions as a tumor suppressor in tumor metastases; however, its role and mechanism in regulating cell migration and invasion of non-small cell…”
Get full text
Journal Article -
2
WBSCR22 Competes with Long Non-coding RNA Linc00346 for miR-509-5p Binding Site to Regulate Cancer Stem Cell Phenotypes of Colorectal Cancer
Published in Biochemical genetics (01-06-2020)“…Various Long non-coding RNAs (lncRNAs) and MicroRNAs (miRNAs) have been demonstrated to be involved in colorectal cancer stem cells (CSCs). WBSCR22 is a key…”
Get full text
Journal Article -
3
The “Hand as Foot” teaching method in lymph nodes staging of non-small cell lung cancer: A clinical experience
Published in Asian journal of surgery (01-11-2021)Get full text
Journal Article -
4
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
Published in Journal of hematology and oncology (08-05-2023)“…QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and…”
Get full text
Journal Article -
5
Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE)
Published in The oncologist (Dayton, Ohio) (01-09-2021)“…Background Real‐world safety and effectiveness data for trastuzumab plus chemotherapy treatment of patients with HER2‐positive metastatic gastric cancer (mGC)…”
Get full text
Journal Article -
6
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial
Published in Clinical cancer research (01-07-2020)“…Our primary purpose is to explore safety and efficacy of high-dose icotinib in comparison with routine-dose icotinib in patients with non-small cell lung…”
Get full text
Journal Article -
7
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer
Published in Journal of clinical oncology (01-06-2022)“…1102 Background: MRG002 is a novel HER2-targeted ADC, composed of a sugar-modified trastuzumab, MMAE payload and a cleavable vc-linker. MRG002 was effective in…”
Get full text
Journal Article -
8
Treatment patterns and long-term clinical outcomes in Chinese patients with nonmetastatic gastric cancer: Results from the non-interventional EVIDENCE registry study
Published in Journal of clinical oncology (01-02-2020)“…Abstract only 307 Background: Although gastric cancer (GC) is a leading cause of cancer-related death in China, important questions about optimal management…”
Get full text
Journal Article -
9
Differentiation antagonizing non-protein coding RNA modulates the proliferation, migration, and angiogenesis of glioma cells by targeting the miR-216a/LGR5 axis and the PI3K/AKT signaling pathway
Published in OncoTargets and therapy (01-01-2019)“…DANCR plays an important role in various types of cancer. However, its role in gliomas remains unclear. In the present study, we aimed to investigate the…”
Get full text
Journal Article -
10
Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE)
Published in Journal of clinical oncology (20-05-2019)“…Abstract only 4025 Background: Gastric cancer (GC) is the second leading cause of cancer-related deaths in China. Trastuzumab (TRA) has been used to treat…”
Get full text
Journal Article -
11
Treatment patterns, effectiveness, and safety of Trastuzumab in Chinese patients with metastatic gastric cancer: Interim analysis of the EVIDENCE registry study
Published in Journal of clinical oncology (20-05-2017)“…Abstract only e15595 Background: Trastuzumab (TRA) was approved for HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma (mGC) in China…”
Get full text
Journal Article -
12
Natural killer cells inhibit oxaliplatin-resistant colorectal cancer by repressing WBSCR22 via upregulating microRNA-146b-5p
Published in American journal of cancer research (01-01-2018)“…Natural killer (NK) cells have exhibited promising efficacy in inhibiting cancer growth. We aimed to explorer the effect of NK cells on oxaliplatin-resistant…”
Get full text
Journal Article -
13
Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1,3-galactosyl epitope–enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy
Published in Cytotherapy (Oxford, England) (01-01-2016)“…Abstract Background aims Refractory B-cell lymphomas are difficult to successfully treat with current chemotherapeutic regimens; however, immunotherapy may be…”
Get full text
Journal Article -
14
Treatment patterns and outcomes in Chinese gastric cancer patients by HER2 status: a non-interventional registry study (EVIDENCE)
Published in The oncologist (Dayton, Ohio) (18-05-2021)“…Real-world safety and effectiveness data for trastuzumab plus chemotherapy treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic…”
Get full text
Journal Article -
15
Cross-sectional analysis of patients with non-mGC in China: An update of EVIDENCE gastric cancer registry study
Published in Journal of clinical oncology (20-01-2015)“…Abstract only 49 Background: According to WHO estimation, > 400,000 new cases of gastric cancer have occurred in 2012 in China, making it the second most…”
Get full text
Journal Article -
16
Interpreting Advanced Breast Cancer Consensus Guidelines for Use in China
Published in Journal of global oncology (01-06-2016)“…Abstract 58 Background: In 2011, an international panel of breast cancer experts developed the first Advanced Breast Cancer (ABC) Consensus Guidelines to…”
Get full text
Journal Article